ArticlePediatric nephrology (Berlin, Germany)2026
Linear growth in pediatric kidney transplant recipients.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth impairment is a major concern in children with chronic kidney disease (CKD). Over the past two decades, recombinant human growth hormone (rhGH) has significantly improved linear growth in this population. Current recommendations support rhGH treatment in children with CKD who have a height below the 3rd percentile or reduced height velocity for age. Following kidney transplantation (KTx), rhGH, is usually deferred during the first post-transplant year until lack of spontaneous catch-up growth has been established. This study aimed to evaluate post-transplant growth in pediatric kidney transplant recipients and to examine its association with key demographic and clinical factors.
methodsThis study included all pediatric patients with kidney failure, who underwent KTx, at Shaare Zedek medical center, between January 2013 and December 2023. Demographic, clinical and laboratory data were retrieved from medical records.
resultsA total of 62 patients were included. Mean height standard deviation score (SDS) improved from - 2.08 two years pre-KTx to - 1.6 two years post-KTx. Most growth gain occurred in the first-year post-KTx. Use of rhGH was associated with significant improvement in linear growth. Preemptive transplantation and parental height were significantly associated with better growth outcomes. Need for rhGH before transplantation was associated with lower height SDS at all time points, although these patients demonstrated a similar degree of improvement over time.
conclusionsPreemptive transplantation was associated with improved linear growth. Ongoing growth monitoring after KTx may enable early identification of suboptimal growth and timely reintroduction of rhGH treatment.
Indexed as
Identifiers
42557503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.